Research
Hormonal
GLP-1/dual agonists were associated with a 54% lower incidence of physician-reported sleep apnea (PRSA).
Practitioners may consider GLP-1/dual agonists as a treatment option to reduce the incidence of sleep apnea in patients with obesity and type 2 diabetes.
StrongSupportsmedium confidence
Overall, GLP-1/dual agonists were associated with a 54% lower incidence of PRSA (HR, 0.46 [95% CI, 0.45-0.49]).
Why this rating
Based on a large retrospective cohort study design.
Source
Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study
Beatriz S Prado et al. · Annals of the American Thoracic Society · 2026
DOI 10.1093/annalsats/aaoaf071
cohort · n=1253188Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →